http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
-
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
-
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
-
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
-
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
-
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
-
Cytosorbents (CTSO) Provides Update on the STAR-T Trial, Reports Final Independent Data and Safety Monitoring Board Recommendation
-
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
-
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
-
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
-
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
-
CytoSorbents to Present at the 8th Annual Dawson James Conference
-
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
-
Cytosorbents (CTSO) Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
-
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
-
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
-
Cytosorbents (CTSO) Announces CFO Resignation
-
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
-
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
-
CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial
-
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
-
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
-
Cytosorbents (CTSO) Appoints Alexander D’Amico as CFO
-
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
-
Cytosorbents (CTSO) And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
-
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
-
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
-
Cytosorbents (CTSO) Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial
-
CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
-
CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference
-
CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference
-
CytoSorbents Reports First Quarter 2023 Results
-
CytoSorbents Reports First Quarter 2023 Results
-
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
-
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
-
Cytosorbents (CTSO) Pivotal STAR-T Trial Reaches Second Key Milestone
-
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
-
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
-
Cytosorbents (CTSO) Announces Retirement of Board Chair
-
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
-
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
-
Cytosorbents (CTSO) Reports Publication Underscoring Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
-
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
-
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
-
Cytosorbents (CTSO) Highlights New Clinical Data from Current Studies
-
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
-
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
-
CytoSorbents Comments on Bank Exposure and Diversified Cash Position
-
CytoSorbents Comments on Bank Exposure and Diversified Cash Position
-
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results

